Fagron Recalls 2 Lots of Neostigmine Methylsulfate

Fagron Sterile Services has recalled two lots of neostigmine methylsulfate 5ml syringes after a confirmed customer complaint that some syringe units are incorrectly labeled as neostigmine methylsulfate 1mg/ml, 3mg per 3ml. “In the event that 5ml rather than the intended 3ml is administered to a patient, adverse events from Neostigmine Methylsulfate overdosage can range from nausea, vomiting, diarrhea, excessive salivation and sweating, increased bronchial secretions, miosis, bradycardia or tachycardia, cardiospasm, bronchospasm, incoordination, muscle cramps, fasciculation, paralysis, to cholinergic crisis resulting in death,” a recall notice says. Neostigmine methylsulfate injection is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. To date, Fagron says it has not received any reports of adverse events or injuries related to this recall.